COVID-19 Rapid Antigen Test as Screening Strategy at Points of Entry: Experience in Lazio Region, Central Italy, August-October 2020.
Animals
Antigens, Viral
/ immunology
COVID-19
/ diagnosis
COVID-19 Testing
/ methods
Chlorocebus aethiops
Humans
Immunoassay
/ methods
Italy
Mass Screening
/ methods
Pandemics
/ prevention & control
Point-of-Care Testing
ROC Curve
Real-Time Polymerase Chain Reaction
SARS-CoV-2
/ genetics
Sensitivity and Specificity
Vero Cells
Italy
SARS-CoV-2
point of entry
rapid antigen test
Journal
Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414
Informations de publication
Date de publication:
13 03 2021
13 03 2021
Historique:
received:
11
02
2021
revised:
09
03
2021
accepted:
11
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
23
4
2021
Statut:
epublish
Résumé
COVID-19 pandemic is a dramatic health, social and economic global challenge. There is urgent need to maximize testing capacity. Rapid Antigen Tests (RAT) represent good candidates for point-of-care and mass surveillance testing to rapidly identify SARS-CoV-2-infected people, counterbalancing lower sensitivity vs. gold standard molecular tests with fast results and possible recurrent testing. We describe the results obtained with the testing algorithm implemented at points of entry (airports and ports) in the Lazio Region (Italy), using the STANDARD F COVID-19 Antigen Fluorescence ImmunoAssay (FIA), followed by molecular confirmation of FIA-positive samples. From mid-August to mid-October 2020, 73,643 RAT were reported to the Regional Surveillance Information System for travelers at points of entry in Lazio Region. Of these, 1176 (1.6%) were FIA-positive, and the proportion of RT-PCR-confirmed samples was 40.5%. Our data show that the probability of confirmation was directly dependent from the semi-quantitative FIA results. In addition, the molecularly confirmed samples were those with high levels of virus and that were actually harboring infectious virus. These results support public health strategies based on early mass screening campaigns by RAT in settings where molecular testing is not feasible or easily accessible, such as points of entry. This approach would contribute to promptly controlling viral spread through travel, which is now of particular concern due to the spread of SARS-CoV-2 variants.
Identifiants
pubmed: 33805832
pii: biom11030425
doi: 10.3390/biom11030425
pmc: PMC7999510
pii:
doi:
Substances chimiques
Antigens, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Ministero della Salute
ID : Ricerca Corrente - linea 1
Organisme : Ministero della Salute
ID : COVID-2020-12371817
Organisme : European Commission
ID : 101003544 - CoNVat
Organisme : European Commission
ID : 101005111-DECISION
Organisme : European Commission
ID : 101005075-KRONO
Organisme : European Commission
ID : European Virus Archive - GLOBAL (grants no. 653316 and no. 871029)
Organisme : Regione Lazio
ID : Health Authority
Références
Euro Surveill. 2020 Apr;25(14):
pubmed: 32290902
J Clin Virol. 2020 Nov;132:104654
pubmed: 33053494
Biochem Biophys Res Commun. 2021 Jan 29;538:226-230
pubmed: 33139015
Nat Rev Microbiol. 2021 Mar;19(3):171-183
pubmed: 33057203
Clin Microbiol Infect. 2021 Mar;27(3):487-488
pubmed: 32979567
J Clin Microbiol. 2020 Oct 21;58(11):
pubmed: 32843531
N Engl J Med. 2020 Nov 26;383(22):e120
pubmed: 32997903
Open Forum Infect Dis. 2020 Sep 02;7(10):ofaa403
pubmed: 33527081
Int J Infect Dis. 2021 Mar;104:282-286
pubmed: 33130198
Int J Infect Dis. 2020 Oct;99:328-333
pubmed: 32497809
JAMA. 2020 Nov 10;324(18):1813-1815
pubmed: 33084882
J Clin Virol. 2020 Aug;129:104500
pubmed: 32585619